Therefore, using the eQTLgen database and MR methods, we have identified six potential drug targets (CHEK2, GOLPH3, PEX10, PLCH2, RP3-395M20.2, RP3-395M20.3) for HCC. This evidence concerns the gene PLCH2 and hepatocellular carcinoma.